$323 Million is the total value of MPM ASSET MANAGEMENT LLC's 15 reported holdings in Q1 2016. The portfolio turnover from Q4 2015 to Q1 2016 was - .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| SNDX | New | Syndax Pharmaceuticals, Inc. | $28,887,000 | – | 2,168,691 | +100.0% | 8.95% | – |
| ELGX | New | Endologix, Inc. | $9,375,000 | – | 1,121,447 | +100.0% | 2.90% | – |
| ETRM | New | EnteroMedics, Inc. | $72,000 | – | 74,206 | +100.0% | 0.02% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2016-05-11
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| Chiasma, Inc. | 24 | Q2 2021 | 19.8% |
| Aratana Therapeutics, Inc. | 24 | Q1 2019 | 26.8% |
| Conatus Pharmaceuticals, Inc. | 23 | Q1 2019 | 9.7% |
| Rhythm Pharmaceuticals, Inc. | 19 | Q2 2022 | 69.9% |
| Harpoon Therapeutics, Inc. | 19 | Q3 2023 | 31.9% |
| Syndax Pharmaceuticals, Inc. | 19 | Q3 2020 | 14.5% |
| Radius Health, Inc. | 17 | Q2 2018 | 76.4% |
| TCR2 Therapeutics, Inc. | 17 | Q1 2023 | 29.1% |
| Proteon Therapeutics, Inc. | 17 | Q4 2018 | 3.0% |
| EpiZyme, Inc. | 15 | Q4 2016 | 35.9% |
View MPM ASSET MANAGEMENT LLC's complete holdings history.
Latest filings
| Type | Filed |
|---|---|
| 13F-HR | 2024-05-15 |
| 13F-HR | 2024-02-13 |
| 13F-HR | 2023-11-14 |
| 13F-HR/A | 2023-09-07 |
| 13F-HR | 2023-08-14 |
| 4 | 2023-06-05 |
| 4 | 2023-05-24 |
| 13F-HR | 2023-05-12 |
| 13F-HR | 2023-02-14 |
| 13F-HR | 2022-11-14 |
View MPM ASSET MANAGEMENT LLC's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.